Entero Healthcare Solutions Limited, one of India’s fastest-growing healthcare distribution platforms, has completed the acquisition of a 51.5% majority stake in Anand Chemiceutics Private Limited for a consideration in the range of ₹210–230 crore, the company said in a regulatory filing.
The acquisition marks Entero’s strategic entry into the fast-expanding diagnostics and medical technology (MedTech) distribution segment, significantly strengthening its presence beyond pharmaceuticals and consumables.
Founded in 2003, Anand Chemiceutics is a leading pan-India distributor of diagnostic equipment, reagents, and medical devices, and serves as a preferred distribution partner for several global diagnostics and MedTech companies. The company services over 1,500 laboratories, hospitals, and government healthcare institutions across India and offers end-to-end turnkey solutions for hospitals and diagnostic centres.
With strong technical expertise across advanced diagnostics, including genomics, Anand Chemiceutics brings specialized application and service support capabilities to Entero’s largely pharma-focused distribution network.
Commenting on the acquisition, Prabhat Agrawal, Managing Director and CEO of Entero Healthcare, said the transaction would accelerate the company’s ambition of building an integrated healthcare supply chain platform. “Anand Chemiceutics’ strong legacy, global partnerships and MedTech expertise, combined with Entero’s scale and technology, position us to build meaningful scale in this high-growth segment,” he said.
Jayesh Sancheti, Managing Director of Anand Chemiceutics, said the transaction represented a strategic integration rather than a simple financial investment. “This partnership combines Anand’s trusted diagnostics platform with Entero’s distribution scale and digital capabilities to create a differentiated healthcare solutions provider,” he said.
Entero had first announced the proposed acquisition in November 2025. Following the completion of the transaction, the company expects its MedTech business to contribute over ₹1,000 crore in annualised revenue in the next financial year, reflecting a sharp expansion in its addressable market.
Headquartered in Pune, Anand Chemiceutics has regional offices in Mumbai, Gurugram and Bengaluru, with deep exposure to PPP projects, chain laboratories, and hospital networks. Entero, founded in 2018, operates one of India’s largest B2B healthcare distribution platforms, powered by its proprietary digital platform, Entero Direct, which integrates inventory management, logistics, and data intelligence across the pharmaceutical supply chain.